Rebecca Chambers
Known title: Chief Financial OfficerCIK: 0001823563
Associated companies
Transaction History
| VCYT | ▼ Sell | Open Market | 2,477 | $106K | 9/4/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,175 | $51K | 9/4/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,603 | $162K | 9/2/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,600 | $79K | 6/4/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,961 | $98K | 6/4/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,693 | $177K | 6/2/2026 | View on chart |
| VCYT | ▲ Buy | Grant | 36,181 | $0 | 3/6/2026 | View on chart |
| VCYT | ▲ Buy | Grant | 13,157 | $0 | 3/6/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 4,400 | $156K | 3/4/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 13,941 | $506K | 3/4/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 7,234 | $260K | 3/2/2026 | View on chart |
| VCYT | ▲ Buy | Grant | 59,324 | $0 | 2/26/2026 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 12,049 | $467K | 2/26/2026 | View on chart |
| VCYT | ▼ Sell | Open Market | 8,537 | $398K | 12/4/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 4,741 | $224K | 12/4/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,384 | $156K | 12/2/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 7,000 | $287K | 11/5/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 5,371 | $162K | 9/2/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 5,370 | $144K | 6/2/2025 | View on chart |
| VCYT | ▲ Buy | Grant | 30,200 | $0 | 3/6/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 11,070 | $385K | 3/2/2025 | View on chart |
| VCYT | ▲ Buy | Grant | 23,170 | $0 | 2/27/2025 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 11,911 | $403K | 2/27/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 527 | $23K | 2/3/2025 | View on chart |
| VCYT | ▼ Sell | Open Market | 7,000 | $303K | 12/3/2024 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,464 | $153K | 12/2/2024 | View on chart |
| VCYT | ▼ Sell | Open Market | 15,275 | $586K | 11/12/2024 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,464 | $109K | 9/2/2024 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,462 | $72K | 6/2/2024 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 2,189 | $46K | 3/15/2024 | View on chart |
| VCYT | ▲ Buy | Grant | 4,318 | $0 | 3/15/2024 | View on chart |
| VCYT | ▲ Buy | Grant | 59,856 | $0 | 3/6/2024 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 6,112 | $147K | 3/2/2024 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 1,800 | $48K | 12/2/2023 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,652 | $98K | 9/2/2023 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 1,183 | $32K | 6/2/2023 | View on chart |
| VCYT | ▲ Buy | Grant | 26,014 | $0 | 3/6/2023 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 2,726 | $66K | 3/2/2023 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 735 | $21K | 12/2/2022 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 3,023 | $58K | 9/2/2022 | View on chart |
| VCYT | ▲ Buy | Grant | 21,404 | $0 | 8/5/2022 | View on chart |
| VCYT | ▲ Buy | Grant | 20,728 | $0 | 3/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.